Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients
To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer’s disease (AD), we studied correlations betw...
Gespeichert in:
| Veröffentlicht in: | Dementia and geriatric cognitive disorders 2003-01, Vol.16 (3), p.119-125 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 125 |
|---|---|
| container_issue | 3 |
| container_start_page | 119 |
| container_title | Dementia and geriatric cognitive disorders |
| container_volume | 16 |
| creator | Tanaka, Yuriko Hanyu, Haruo Sakurai, Hirofumi Takasaki, Masaru Abe, Kimihiko |
| description | To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer’s disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy. Eighty-two patients were divided into responders, including transiently and continuously responding groups, and nonresponders, based on the changes in the Mini-Mental State Examination (MMSE) score from baseline at 3 months and at 12 months. Atrophy of the substantia innominata was more pronounced in transiently and continuously responding groups than nonresponders, but no significant change in the thickness between transiently and continuously responding groups was found. The MMSE score changes from baseline at 3 months and at 12 months significantly inversely correlated with the thickness of the substantia innominata. Logistic regression analysis revealed that the overall discrimination rate with the thickness of the substantia innominata was 70% between responders and nonresponders. We conclude that atrophy of the substantia innominata on MRI helps to predict response to donepezil treatment in patients with AD. |
| doi_str_mv | 10.1159/000070998 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73416813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73416813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-4c66d3b6e1eb3dec9f7b8e93ee27d0786369f251afb4ca419af66bc1034675113</originalsourceid><addsrcrecordid>eNqF0U1rFDEYB_BBFFurB8-ChIKCh9G8bV6OS7dqocWi9TxkMs_sps4k0yR7aE9-AT-AX89PYra7tiCCuSTw_PiHh39VPSf4LSEz_Q6XI7HW6kG1TzgltVaUP7x941phrPaqJyldbtRM6MfVHqGKCsnEfvVjnmOYVtco9CivAH1Ztykbn51BzvswOm-yQcGjM7P0kJ1FnyEFb7wFdDKapfNLdB6hczanzWgKPgHKAS2Chwlu3IAuIpg8gs8lEc2HmxW4EeKv7z8TWrgEpvhzk10B6Wn1qDdDgme7-6D6-v744uhjffrpw8nR_LS2XNFccytEx1oBBFrWgdW9bBVoBkBlh6USTOiezojpW24NJ9r0QrSWYMaFnBHCDqrX29wphqs1pNyMLlkYBuMhrFMjGSdCEfZfSLEmQvJN4uFf8DKsoy9LNJRhrqUisqA3W2RjSClC30zRjSZeNwQ3myabuyaLfbkLXLcjdPdyV10Br3bAJGuGPpZOXLp3XBOMNS3uxdZ9M3EJ8Q78-ebwn9PF8dktaKauZ78Bmyi8GQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230497817</pqid></control><display><type>article</type><title>Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients</title><source>Karger Journals</source><source>MEDLINE</source><creator>Tanaka, Yuriko ; Hanyu, Haruo ; Sakurai, Hirofumi ; Takasaki, Masaru ; Abe, Kimihiko</creator><creatorcontrib>Tanaka, Yuriko ; Hanyu, Haruo ; Sakurai, Hirofumi ; Takasaki, Masaru ; Abe, Kimihiko</creatorcontrib><description>To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer’s disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy. Eighty-two patients were divided into responders, including transiently and continuously responding groups, and nonresponders, based on the changes in the Mini-Mental State Examination (MMSE) score from baseline at 3 months and at 12 months. Atrophy of the substantia innominata was more pronounced in transiently and continuously responding groups than nonresponders, but no significant change in the thickness between transiently and continuously responding groups was found. The MMSE score changes from baseline at 3 months and at 12 months significantly inversely correlated with the thickness of the substantia innominata. Logistic regression analysis revealed that the overall discrimination rate with the thickness of the substantia innominata was 70% between responders and nonresponders. We conclude that atrophy of the substantia innominata on MRI helps to predict response to donepezil treatment in patients with AD.</description><identifier>ISSN: 1420-8008</identifier><identifier>EISSN: 1421-9824</identifier><identifier>DOI: 10.1159/000070998</identifier><identifier>PMID: 12826736</identifier><identifier>CODEN: DGCDFX</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Aged ; Alzheimer Disease - diagnosis ; Alzheimer Disease - drug therapy ; Atrophy ; Biological and medical sciences ; Cholinesterase Inhibitors - therapeutic use ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; Humans ; Indans - therapeutic use ; Logistic Models ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Neurology ; Neuropharmacology ; Original Research Article ; Pharmacology. Drug treatments ; Piperidines - therapeutic use ; Prognosis ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Substantia Innominata - pathology ; Treatment Outcome</subject><ispartof>Dementia and geriatric cognitive disorders, 2003-01, Vol.16 (3), p.119-125</ispartof><rights>2003 S. Karger AG, Basel</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 S. Karger AG, Basel</rights><rights>Copyright S. Karger AG 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-4c66d3b6e1eb3dec9f7b8e93ee27d0786369f251afb4ca419af66bc1034675113</citedby><cites>FETCH-LOGICAL-c482t-4c66d3b6e1eb3dec9f7b8e93ee27d0786369f251afb4ca419af66bc1034675113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14910092$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12826736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Yuriko</creatorcontrib><creatorcontrib>Hanyu, Haruo</creatorcontrib><creatorcontrib>Sakurai, Hirofumi</creatorcontrib><creatorcontrib>Takasaki, Masaru</creatorcontrib><creatorcontrib>Abe, Kimihiko</creatorcontrib><title>Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients</title><title>Dementia and geriatric cognitive disorders</title><addtitle>Dement Geriatr Cogn Disord</addtitle><description>To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer’s disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy. Eighty-two patients were divided into responders, including transiently and continuously responding groups, and nonresponders, based on the changes in the Mini-Mental State Examination (MMSE) score from baseline at 3 months and at 12 months. Atrophy of the substantia innominata was more pronounced in transiently and continuously responding groups than nonresponders, but no significant change in the thickness between transiently and continuously responding groups was found. The MMSE score changes from baseline at 3 months and at 12 months significantly inversely correlated with the thickness of the substantia innominata. Logistic regression analysis revealed that the overall discrimination rate with the thickness of the substantia innominata was 70% between responders and nonresponders. We conclude that atrophy of the substantia innominata on MRI helps to predict response to donepezil treatment in patients with AD.</description><subject>Aged</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Atrophy</subject><subject>Biological and medical sciences</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>Humans</subject><subject>Indans - therapeutic use</subject><subject>Logistic Models</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Original Research Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - therapeutic use</subject><subject>Prognosis</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Substantia Innominata - pathology</subject><subject>Treatment Outcome</subject><issn>1420-8008</issn><issn>1421-9824</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0U1rFDEYB_BBFFurB8-ChIKCh9G8bV6OS7dqocWi9TxkMs_sps4k0yR7aE9-AT-AX89PYra7tiCCuSTw_PiHh39VPSf4LSEz_Q6XI7HW6kG1TzgltVaUP7x941phrPaqJyldbtRM6MfVHqGKCsnEfvVjnmOYVtco9CivAH1Ztykbn51BzvswOm-yQcGjM7P0kJ1FnyEFb7wFdDKapfNLdB6hczanzWgKPgHKAS2Chwlu3IAuIpg8gs8lEc2HmxW4EeKv7z8TWrgEpvhzk10B6Wn1qDdDgme7-6D6-v744uhjffrpw8nR_LS2XNFccytEx1oBBFrWgdW9bBVoBkBlh6USTOiezojpW24NJ9r0QrSWYMaFnBHCDqrX29wphqs1pNyMLlkYBuMhrFMjGSdCEfZfSLEmQvJN4uFf8DKsoy9LNJRhrqUisqA3W2RjSClC30zRjSZeNwQ3myabuyaLfbkLXLcjdPdyV10Br3bAJGuGPpZOXLp3XBOMNS3uxdZ9M3EJ8Q78-ebwn9PF8dktaKauZ78Bmyi8GQ</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Tanaka, Yuriko</creator><creator>Hanyu, Haruo</creator><creator>Sakurai, Hirofumi</creator><creator>Takasaki, Masaru</creator><creator>Abe, Kimihiko</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>88J</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>M2R</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20030101</creationdate><title>Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients</title><author>Tanaka, Yuriko ; Hanyu, Haruo ; Sakurai, Hirofumi ; Takasaki, Masaru ; Abe, Kimihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-4c66d3b6e1eb3dec9f7b8e93ee27d0786369f251afb4ca419af66bc1034675113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Atrophy</topic><topic>Biological and medical sciences</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>Humans</topic><topic>Indans - therapeutic use</topic><topic>Logistic Models</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Original Research Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - therapeutic use</topic><topic>Prognosis</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Substantia Innominata - pathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Yuriko</creatorcontrib><creatorcontrib>Hanyu, Haruo</creatorcontrib><creatorcontrib>Sakurai, Hirofumi</creatorcontrib><creatorcontrib>Takasaki, Masaru</creatorcontrib><creatorcontrib>Abe, Kimihiko</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Database</collection><collection>Social Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Dementia and geriatric cognitive disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Yuriko</au><au>Hanyu, Haruo</au><au>Sakurai, Hirofumi</au><au>Takasaki, Masaru</au><au>Abe, Kimihiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients</atitle><jtitle>Dementia and geriatric cognitive disorders</jtitle><addtitle>Dement Geriatr Cogn Disord</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>16</volume><issue>3</issue><spage>119</spage><epage>125</epage><pages>119-125</pages><issn>1420-8008</issn><eissn>1421-9824</eissn><coden>DGCDFX</coden><abstract>To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer’s disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy. Eighty-two patients were divided into responders, including transiently and continuously responding groups, and nonresponders, based on the changes in the Mini-Mental State Examination (MMSE) score from baseline at 3 months and at 12 months. Atrophy of the substantia innominata was more pronounced in transiently and continuously responding groups than nonresponders, but no significant change in the thickness between transiently and continuously responding groups was found. The MMSE score changes from baseline at 3 months and at 12 months significantly inversely correlated with the thickness of the substantia innominata. Logistic regression analysis revealed that the overall discrimination rate with the thickness of the substantia innominata was 70% between responders and nonresponders. We conclude that atrophy of the substantia innominata on MRI helps to predict response to donepezil treatment in patients with AD.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>12826736</pmid><doi>10.1159/000070998</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1420-8008 |
| ispartof | Dementia and geriatric cognitive disorders, 2003-01, Vol.16 (3), p.119-125 |
| issn | 1420-8008 1421-9824 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73416813 |
| source | Karger Journals; MEDLINE |
| subjects | Aged Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Atrophy Biological and medical sciences Cholinesterase Inhibitors - therapeutic use Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Female Humans Indans - therapeutic use Logistic Models Magnetic Resonance Imaging Male Medical sciences Neurology Neuropharmacology Original Research Article Pharmacology. Drug treatments Piperidines - therapeutic use Prognosis Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Substantia Innominata - pathology Treatment Outcome |
| title | Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T16%3A57%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atrophy%20of%20the%20Substantia%20innominata%20on%20Magnetic%20Resonance%20Imaging%20Predicts%20Response%20to%20Donepezil%20Treatment%20in%20Alzheimer%E2%80%99s%20Disease%20Patients&rft.jtitle=Dementia%20and%20geriatric%20cognitive%20disorders&rft.au=Tanaka,%20Yuriko&rft.date=2003-01-01&rft.volume=16&rft.issue=3&rft.spage=119&rft.epage=125&rft.pages=119-125&rft.issn=1420-8008&rft.eissn=1421-9824&rft.coden=DGCDFX&rft_id=info:doi/10.1159/000070998&rft_dat=%3Cproquest_cross%3E73416813%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230497817&rft_id=info:pmid/12826736&rfr_iscdi=true |